Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315326 | 1.00 | GAA (0.46) | GAAL3MBTL1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL4307302 | 0.76 | MAPT (0.40) | GAAL3MBTL1CHRNB2CHRNA4HRH3 | |
| SCHEMBL8223424 | 0.76 | MAPT (0.40) | GAAL3MBTL1CHRNB2CHRNA4HRH3 | |
| SCHEMBL24635866 | 0.76 | CHRNB2 (0.68) | GAAL3MBTL1CHRNB2CHRNA4 | |
| SCHEMBL24028246 | 0.76 | CHRNB2 (0.68) | GAAL3MBTL1CHRNB2CHRNA4 | |
| SCHEMBL10153424 | 0.76 | CHRNB2 (0.68) | GAAL3MBTL1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL30261864 | 0.75 | CHRNB2 (0.67) | GAAL3MBTL1CHRNB2CHRNA4 | |
| SCHEMBL25855534 | 0.72 | GAA (0.46) | GAAL3MBTL1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL25855613 | 0.72 | GAA (0.46) | GAAL3MBTL1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL5374497 | 0.71 | CHRNB2 (0.77) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3267996-B1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10329294-B2 | Pyrazolopyrimidine inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180051028-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | US | disclosed |
| EP-3267996-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016144846-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| WO-2008008517-A2 | BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329294-B2 | Pyrazolopyrimidine inhibitors of IRAK4 activity | IRAK4, IRAK2, IRAK1 | GAA 2123/4885L3MBTL1 1305/4885CHRNB2 4388/4885 |
| US-20180051028-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK2, IRAK1 | GAA 2123/4885L3MBTL1 1305/4885CHRNB2 4388/4885 |
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | GAA 2197/4885L3MBTL1 4413/4885CHRNB2 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.